Martin L. Moore, PhD
Pediatrics, Infectious Diseases
ARTDTP Research Discipline
Anti-infective studies in the Moore lab center around RSV, which is the leading cause of bronchiolitis, viral pneumonia, and viral death in infants as well as the leading cause of respiratory failure and mechanical ventilation in infants. There is no RSV vaccine in use and no widely available therapies. Airway mucus is a hallmark feature of RSV lower respiratory tract infection. Mucus, necrotic epithelial cell debris, and inflammatory cells obstruct the airways in RSV bronchiolitis. The primary goals of the laboratory are to define mechanisms of RSV pathogenesis and to advance vaccine candidates in a robust challenge model. They are using a novel reverse genetics system developed by the group, virulent “mucogenic” RSV strains that they identified, and a mouse model of RSV infection resulting in lung dysfunction in order to achieve these goals. Current vaccine research includes evaluating whether virus-like particle and engineered, live attenuated RSV vaccines can prevent RSV induced lung disease in mice.